Nutriband Inc. Added to Four Russell Indexes, Highlighting Market Recognition and Growth Potential
Nutriband Inc.'s inclusion in four Russell indexes underscores the market's recognition of its AVERSA pipeline and its potential impact on the pharmaceutical industry.
Nutriband Inc. (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. This inclusion is a significant milestone for the company, reflecting its growing market recognition and the momentum behind its AVERSA pipeline. CEO Gareth Sheridan highlighted the potential of AVERSA Fentanyl, which could achieve peak annual U.S. sales between $80 million and $200 million. The Russell indexes, maintained by FTSE Russell, are a benchmark for approximately $10.6 trillion in assets, widely utilized by investment managers and institutions.
The AVERSA technology, developed by Nutriband, is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This innovation is particularly relevant in the context of the ongoing opioid crisis, offering a safer alternative for transdermal pharmaceutical products. The company's focus on abuse-deterrent technologies positions it as a key player in addressing critical public health challenges.
For more details on Nutriband's achievements and its AVERSA pipeline, visit https://ibn.fm/wa35e. Further information about Nutriband Inc. and its innovative technologies can be found at https://www.Nutriband.com.